2026 ASCO GI
Elena Elimova, MD, on HER2-Positive Gastroesophageal Cancer: Zanidatamab Plus Chemotherapy
Elena Elimova, MD, of Princess Margaret Cancer Centre, presents findings from the primary analysis of the phase III HERIZON-GEA-01 trial, which evaluated zanidatamab, a dual HER2-targeted bispecific a...
Elizabeth Smyth, MD, on FLOT Administration in the MATTERHORN Trial
Elizabeth Smyth, MD, of the Oxford NIHR Biomedical Research Centre, Churchill Hospital, presents findings from an analysis of the MATTERHORN trial, a phase III study that examined fluorouracil, leucov...
Samuel J. Klempner, MD, on Advanced Gastric/GEJ Cancer: Zolbetuximab Plus mFOLFOX6 and Nivolumab
Samuel J. Klempner, MD, of Massachusetts General Hospital, discusses results from the phase II ILUSTRO trial, which evaluated the combination of the anti-CLDN18.2 antibody zolbetuximab plus mFOLFOX6 a...
Ghassan K. Abou-Alfa, MD, on Tremelimumab Rechallenge in Unresectable HCC: Safety Outcomes
Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, outlines an assessment of baseline characteristics and safety outcomes in HIMALAYA trial participants who were rechallenged with tr...
Ghassan K. Abou-Alfa, MD, on a Novel First-Line Regimen for Unresectable HCC Under Study
Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, reviews the goals of the upcoming phase III ARTEMIDE-HCC01 trial, which will examine the efficacy and safety of rilvegostomig (a no...
